Aldeyra Therapeutics
ALDX
120 hedge funds and large institutions have $252M invested in Aldeyra Therapeutics in 2023 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 41 increasing their positions, 37 reducing their positions, and 14 closing their positions.
11% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 37
7% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 14
1% more funds holding
Funds holding: 119 → 120 (+1)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
2.18% less ownership
Funds ownership: 66.64% → 64.46% (-2.2%)
23% less capital invested
Capital invested by funds: $328M → $252M (-$75.2M)
38% less call options, than puts
Call options by funds: $1.34M | Put options by funds: $2.16M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$1.04M |
| 2 |
Two Sigma Investments
New York
|
+$1.01M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$999K |
| 4 |
LCM
Laurion Capital Management
New York
|
+$946K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$740K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.02M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$3.47M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$1.54M |
| 4 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$1.42M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
-$1.26M |
ALDX Hedge Fund Activity: Q3 2023 in Review
120 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q3 2023, worth a combined $252M — down 23% from $328M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new ALDX positions and 14 closed out — a net gain of 1 holder — while 41 added to existing stakes and 37 trimmed.
The largest buyer was BlackRock, adding an estimated $1.04M. The largest seller was Fidelity Investments, cutting an estimated $5.02M.
- 120 institutional investors held Aldeyra Therapeutics (ALDX) as of Q3 2023, up from 119 in Q2 2023.
- Funds reported $252M of Aldeyra Therapeutics stock for Q3 2023, down 23% quarter-over-quarter.
- 15 funds opened new Aldeyra Therapeutics positions in Q3 2023 and 14 closed out, a net change of +1 holder.
- The largest Aldeyra Therapeutics buyer in Q3 2023 was BlackRock, an estimated $1.04M added.
- The largest Aldeyra Therapeutics seller in Q3 2023 was Fidelity Investments, an estimated $5.02M sold.
Based on aggregated 13F filings for Q3 2023.